RE
UBX

RBC Europe’s Unity Biotechnology UBX Stock Holding History

RBC Europe’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30
Closed -$900 – 1124
2021
Q3 		$900 Hold
30
– – ﹤0.01% 1185
2021
Q2 		$1.39K Hold
30
– – ﹤0.01% 1160
2021
Q1 		$1.8K Hold
30
– – ﹤0.01% 1088
2020
Q4 		$1.57K Hold
30
– – ﹤0.01% 1062
2020
Q3 		$1.04K Sell
30
-10
-25% -$633 ﹤0.01% 1017
2020
Q2 		$3.47K Hold
40
– – ﹤0.01% 905
2020
Q1 		$2.32K Buy
40
+30
+300% +$1.89K ﹤0.01% 902
2019
Q4 		$721 Hold
10
– – ﹤0.01% 1001
2019
Q3 		$610 Hold
10
– – ﹤0.01% 1005
2019
Q2 		$950 Hold
10
– – ﹤0.01% 1012
2019
Q1 		$811 Hold
10
– – ﹤0.01% 1027
2018
Q4 		$1.63K Hold
10
– – ﹤0.01% 1009
2018
Q3 		$1.63K Buy
+10
New +$1.65K ﹤0.01% 1055

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RBC Europe's UBX Position: Q4 2021 in Review

RBC Europe sold out of Unity Biotechnology (UBX) in Q4 2021, closing a stake of 30 shares — an estimated $900 sold.

RBC Europe first reported a position in UBX in Q3 2018 and held it in 13 quarters. The position peaked at $3.47K in Q2 2020. 71 funds tracked by Wall St. Rank hold UBX as of Q4 2021.

  • RBC Europe reported no remaining Unity Biotechnology position as of Q4 2021 after selling out during the quarter.
  • RBC Europe sold 30 Unity Biotechnology shares in Q4 2021, an estimated $900.
  • RBC Europe first reported a position in Unity Biotechnology in Q3 2018 and held it in 13 quarters.
  • RBC Europe's Unity Biotechnology position peaked at $3.47K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2021.

Based on RBC Europe's 13F filing for Q4 2021, filed 14 Nov 2022.